Several hematological biomarkers, including PAPP‐A, free β‐HCG, natriuretic peptide, and chromosome microarray analysis, have potential value in the early detection of CHD (Miyoshi et al, 2018; Wang et al, 2018b; Alanen et al, 2019; Gu et al, 2019; Bahado‐Singh et al, 2020; Chen et al, 2022). This evidence concerns the gene PAPPA and coronary artery disorder.